On January 12, 2024, Hoche Partners Pharma Holding S.A. announced that on December 07, 2023, it has issued a letter to the Board that described and endorsed certain concerns put forth by another shareholder and requested the calling of a shareholders? meeting to replace the Board. Hoche Partners requested that the Board of Directors call a special shareholders meeting, to take place within one month of receipt of this letter, in accordance with Art.

9.2 of the articles of association of the Company and Art. 450-8 of the law of 10 August 1915 concerning commercial companies, as amended. The agenda for that special shareholders meeting shall include changing the entire Board of Directors and its Chairman.

A new board should be appointed consisting of independent professionals with experience in the pharmaceutical and public companies listed for public trading in the United States. Hoche Partners thus require that the agenda be as follows: 1) revocation with effect as of the date of the shareholders? meeting of all the members of the Board of Directors.

2) appointment with effect as of the date of the shareholders? meeting of seven new members of the Board of Directors We are looking forward to the shareholders meeting. In addition, Hoche Partners stated that on December 25, 2023, Hoche Partners, again issued a letter to the Board setting out in detail, the concerns with the current business and financial affairs at the Company and called for a shareholders?

meeting to replace the Board.